Member Info for Fruitsnveg

No need to wonder Spaceman; I have a diverse range of contacts whose knowledge of the industry I respect. I don't much fret about following the crowd. Slow and steady does it for me.

I would't be so quick to judge 36 visible connections Spacman, versus the many more invisible ones. The craftier execs tend to keep their networks either closed, or low key, especially when it comes to snooping shareholders. He's well known enough, is what I hear.

Dex may be cheaper but it has a whole range of side effects that are significant.

Yes interferon is expensive to make like many drugs, but that needn't always be the case. The top global BP's are investing cutting edge technology and platforms to bring down source and manufacturing costs - longer term I wouldn't see it as a major hurdle for whoever takes it on.

"Then you short it!"

Is that before or after the interim analysis starts being communicated?

...lol

Interesting strategy there, Axe.

Rather than challenge "them about whether b-interferon is any good", I think it would be vastly more informative to PIs here if you could expand on your theory as to why SNG001 would ever work as "an alternative administration technique"? If it was intended to work as a subcutaneous treatment it would have been developed as such, and it clearly has not and for good reason. The difference has been well documented here.

To your overall point perhaps, yes, most drug development is highly risky, and the majority fail. A sobering but ultimately fair assessment.

As for the company having "frittered away all their cash" that is wholly untrue, as the latest balance sheet quite clearly evidences.

Likewise. I think that's a good observation Dippfs.

SS's comment on finance is noteworthy:

"SS: I completely understand your thought process, but just to confirm, it’s you saying £50M…we have not said that so please don’t spread that as lore on the chat boards. We are understanding of what you’ve said and all will be revealed in the package we will announce shortly. Rest assured we have explored all options for funding."

Interesting - 50M is not a figure the company have given or committed to. It sounds, from that comment, like it could be quite a bit less (and very unlikely to be more)?

Thanks Chaps - really useful notetaking. Appreciate the effort.

"TFG are naturally going to set (accept) the price low so they can own a large chunk of the company for not much. Eek"

That's not their MO. Did anyone notice them at the AGM...?

Stranger things have happened Bob.

Yes, it was at 10:00am last year.

BobFraeberks,

Interestingly our NED Flic Gabbay, (in her role as SVP of Transcrip), happens to be on the Commercial Research Delivery Centres (CRDCs) membership selection Committee. That may prove useful?

https://www.nihr.ac.uk/membership-selection-committee-nihr-commercial-research-delivery-centres-crdcs-2024#:~:text=Dr%20Flic%20Gabbay.%20Senior%20Vice%20President,%20tranScrip.%20Professor%20Kerenza%20Hood

Bob,

You may well be right, I wouldn't rule out SCTU being involved, it is certainly well placed vis-a-vis respiratory research.

The US link also has me a little excited! Whether BARDA or a private co-development, I don't really mind (although truth be told, I think a private partner, BP or otherwise, might prove quicker than the sloth-like speed of US Gov programmes, but I won't look a gift horse in the mouth. All positive signs will be welcome.

Still smarting over the seasonality of viruses quip I see Docdoc….,

Dippfs

Do t conflate a Brokers Note with company statement. Cavendish give their opinions based on what they know - they have to follow strict regulatory rules when making statement s to investors and theirs is simply an opinion. They seem to have applied a broad brush here - could be 6 months, could be 12 months. That’s to cover themselves. The better question in my view is likelihood of being one or the other.

No doubt you found my last remark triggering DocDan. look forward to hearing your opinion.

Bear in mind too that the old argument of potentially 'missing a Winter season' has been be-bunked a few times now. Lots of these viruses that send people to ICU don't suddenly stop circulating in March or January or whenever. And US involvement possibly extends our trialling window given the geographical reach.

With 2 regulators to satisfy (spanning 2 territories), I don't think it'll be a rushed affair and that will be down to necessity (the amount of work involved with dependent collaborators, rather than them wasting time. I see the spend a necessary part of the journey to drug approval. As Marsden said today, they've been very busy with the "obvious and less obvious" stuff. A lot of work will be going into running a successful trial - it's potentially our last shot. Ref Cavendish note, it sounds like best case scenario is trial to start by end March, if funding agreed for that to happen. Sounds reasonable to me that they will need to spend more time and money to get to trial Day 1, it's no small undertaking.

Dippfs, agree.

Also the US angle. I think there's more to that we probably haven't yet considered.

I admire your sleuthing Costas. Mr Costs meets Miss Marple.